Why Is Coinbase Stock Going Down?
Every way you look at it, Coinbase has had a…
Buy
53
SYK Quote, Financials, Valuation and Earnings
Last price:
$367.13
Seasonality move
:
5.89%
Day range:
$364.79 - $369.67
52-week range:
$292.43 - $398.20
Dividend yield:
0.87%
P/E ratio:
39.35x
P/S ratio:
6.43x
P/B ratio:
6.95x
Volume:
699.8K
Avg. volume:
1.3M
1-year change:
22.78%
Market cap:
$139.9B
Revenue:
$20.5B
EPS (TTM):
$9.33
Analysts' Opinion
-
Consensus RatingStryker has received a consensus rating of Buy. The company's average rating is a Buy based on 13 Buy ratings, 9 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $406.60, Stryker has an estimated upside of 10.76% from its current price of $367.11.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $276.00 representing 100% downside risk from its current price of $367.11.
Fair Value
-
According to the consensus of 22 analysts, Stryker has 10.76% upside to fair value with a price target of $406.60 per share.
SYK vs. S&P 500
-
Over the past 5 trading days, Stryker has overperformed the S&P 500 by 2.1% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Stryker does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Stryker has grown year-over-year revenues for 17 quarters straight. In the most recent quarter Stryker reported revenues of $5.5B.
Earnings Growth
-
Stryker has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Stryker reported earnings per share of $2.16.
Enterprise value:
150.7B
EV / Invested capital:
4.23x
Price / LTM sales:
6.43x
EV / EBIT:
34.39x
EV / Revenue:
6.86x
PEG ratio (5yr expected):
1.02x
EV / Free cash flow:
47.04x
Price / Operating cash flow:
44.09x
Enterprise value / EBITDA:
27.82x
Gross Profit (TTM):
$14B
Return On Assets:
8.96%
Net Income Margin (TTM):
16.34%
Return On Equity:
18.78%
Return On Invested Capital:
11.09%
Operating Margin:
19.75%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $17.9B | $19.9B | $22B | $4.9B | $5.5B | |
| Gross Profit | $11.4B | $12.6B | $14B | $3.2B | $3.5B | |
| Operating Income | $2.9B | $3.6B | $4.4B | $931M | $1.1B | |
| EBITDA | $3.8B | $4.7B | $5.4B | $1.2B | $1.4B | |
| Diluted EPS | $6.43 | $6.74 | $9.33 | $1.80 | $2.16 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $13.5B | $9.5B | $9.3B | $11B | $14.7B | |
| Total Assets | $32.3B | $34.1B | $36B | $38B | $43.8B | |
| Current Liabilities | $4.7B | $4.4B | $4.6B | $7.5B | $7.7B | |
| Total Liabilities | $19.3B | $20B | $19.5B | $20.1B | $23.7B | |
| Total Equity | $13B | $14.2B | $16.5B | $17.9B | $20.1B | |
| Total Debt | $13.1B | $12.7B | $12.8B | $12.7B | $15.5B | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $2.6B | $3.2B | $3.8B | $1.1B | $1.5B | |
| Cash From Investing | -$3.1B | -$972M | -$2.8B | -$145M | -$2.2B | |
| Cash From Financing | -$591M | -$1.8B | $983M | -$422M | $2.7B | |
| Free Cash Flow | $2B | $2.6B | $3.2B | $902M | $1.3B | |
SYK
Sector
Market Cap
$139.9B
$45.9M
Price % of 52-Week High
92.19%
46.95%
Dividend Yield
0.87%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
22.78%
-32.15%
Beta (5-Year)
0.938
0.772
Dividend yield:
0.87%
Annualized payout:
$3.05
Payout ratio:
33.4%
Growth streak:
14 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$365.69
200-day SMA
Buy
Level
$351.58
Bollinger Bands (100)
Buy
Level
347.14 - 380.36
Chaikin Money Flow
Buy
Level
401.4M
20-day SMA
Sell
Level
$375.89
Relative Strength Index (RSI14)
Sell
Level
42.65
ADX Line
Buy
Level
16.01
Williams %R
Neutral
Level
-63.7284
50-day SMA
Sell
Level
$374.81
MACD (12, 26)
Sell
Level
-3.53
25-day Aroon Oscillator
Sell
Level
-56
On Balance Volume
Neutral
Level
163.4M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (4.7665)
Buy
CA Score
(Annual)
Level (0.0121)
Buy
Beneish M-Score
(Annual)
Level (-2.5012)
Buy
Momentum Score
Level (8)
Buy
Ohlson Score
Level (-1.47)
Buy
Piotroski F Score
(Annual)
Level (8)
Buy
Quality Ratio Score
Level (5)
Buy
Fundamental Score
Level (10)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Stryker designs, manufactures, and markets an array of medical equipment, instruments, consumable supplies, and implantable devices. The product portfolio includes hip and knee replacements, extremities, endoscopy systems, operating room equipment, embolic coils, hospital beds and gurneys, and orthopedic robotics. Stryker remains one of the three largest competitors in reconstructive orthopedic implants and holds the leadership position in operating room equipment. Just over one fourth of Stryker's total revenue currently comes from outside the United States.
Stock Forecast FAQ
In the current month, SYK has received 13 Buy ratings 9 Hold ratings, and 0 Sell ratings. The SYK average analyst price target in the past 3 months is $406.60.
-
Where Will Stryker Stock Be In 1 Year?
According to analysts, the consensus estimate is that Stryker share price will rise to $406.60 per share over the next 12 months.
-
What Do Analysts Say About Stryker?
Analysts are divided on their view about Stryker share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Stryker is a Sell and believe this share price will drop from its current level to $276.00.
-
What Is Stryker's Price Target?
The price target for Stryker over the next 1-year time period is forecast to be $406.60 according to 22 Wall Street analysts, 13 of them rate the stock a Buy, 0 rate the stock a Sell, and 9 analysts rate the stock a Hold.
-
Is SYK A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Stryker is a Buy. 13 of 22 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of SYK?
You can purchase shares of Stryker via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Stryker shares.
-
What Is The Stryker Share Price Today?
Stryker was last trading at $367.13 per share. This represents the most recent stock quote for Stryker. Yesterday, Stryker closed at $367.11 per share.
-
How To Buy Stryker Stock Online?
In order to purchase Stryker stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Uber Stock a Buy on the Dip?
Shares of Uber Technologies (NYSE:UBER) have been fading fast in…
Is AMD Stock an All-Time Buy?
Advanced Micro Devices (NASDAQ:AMD) is a high-growth AI stock that…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 28
Lemonade [LMND] is down 10.69% over the past day.
Sell
50
TSLL alert for Dec 28
Direxion Daily TSLA Bull 2X Shares [TSLL] is down 9.92% over the past day.
Buy
63
SMLR alert for Dec 28
Semler Scientific [SMLR] is down 9.65% over the past day.
